University of Adelaide, Adelaide, South Australia, Australia.
Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
Commun Dis Intell (2018). 2020 Oct 15;44. doi: 10.33321/cdi.2020.44.80.
The Australian Group on Antimicrobial Resistance (AGAR) performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric gram-negative pathogens. The 2018 survey was the sixth year to focus on bloodstream infections, and included Enterobacterales, and species. Eight thousand eight hundred and fifty-seven isolates, comprising Enterobacterales (7,983; 90.1%), (764; 8.6%) and species (110; 1.2%), were tested using commercial automated methods. The results were analysed using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (January 2020). Of the key resistances, resistance to the third-generation cephalosporin ceftriaxone was found in 13.3%/13.3% (CLSI/EUCAST criteria) of and 8.4%/8.4% of . Resistance rates to ciprofloxacin were 16.0%/16.0% for , 10.2%/10.2% for complex, 5.9%/5.9% for complex, and 4.1%/9.3% for . Resistance rates to piperacillin-tazobactam were 3.2%/5.7%, 4.7%/8.5%, 14.8%/21.4%, and 6.9%/12.5% for the same four species/complex respectively. Twenty-nine isolates from 29 patients were shown to harbour a carbapenemase gene: 15 , five , four (one with also), three , one , and one .
澳大利亚抗菌药物耐药性监测组（AGAR）定期进行流行率研究，以监测选定肠道革兰氏阴性病原体的抗菌药物耐药性变化。2018 年的调查是第六年重点关注血流感染，包括肠杆菌科和 物种。使用商业自动化方法测试了 8857 株分离株，包括肠杆菌科（7983 株；90.1%）、 （764 株；8.6%）和 物种（110 株；1.2%）。使用临床和实验室标准协会（CLSI）和欧洲抗菌药物敏感性测试委员会（EUCAST）标准（2020 年 1 月）分析结果。在关键耐药性方面，第三代头孢菌素头孢曲松的耐药性在 和 中分别为 13.3%/13.3%（CLSI/EUCAST 标准）和 8.4%/8.4%。对环丙沙星的耐药率分别为 16.0%/16.0%、10.2%/10.2%、5.9%/5.9%和 4.1%/9.3%。哌拉西林-他唑巴坦的耐药率分别为 3.2%/5.7%、4.7%/8.5%、14.8%/21.4%和 6.9%/12.5%，适用于上述四种菌/复合菌。从 29 名患者的 29 株分离株中检测到携带碳青霉烯酶基因：15 株 ，5 株 ，4 株 （一株同时携带 ），3 株 ，1 株 ，1 株 。
